Sanofi India Ltd
Sanofi India Ltd Share Price Today: Live Updates & Key Insights
Get insights on Sanofi India Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Sanofi India Ltd Share Price Chart
Sanofi India Ltd Fundamentals
Traded Volume: 14,887
Market Cap(Cr): 10,393
Avg Traded Price 4536.75
1 Year return -25.74%
Upper Circuit 4,588.7
Lower Circuit 4,503
P/E TTM 29.00
P/B Ratio 155.00
Traded Value(Cr) 671.82
EPS TTM 154.707
Book value 154.707
Dividend 4.00%
Sanofi India Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Sanofi India Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Sanofi India Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -1.59%
1M -3.97%
3M -12.65%
1Y -25.74%
YTD -24.94%
Sanofi India Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Sanofi India Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 14962.00
Day Before Yesterday 12279.00
1W Avg 12432.60
1M Avg 21328.48
3M Avg 15099.90
Sanofi India Ltd Technical Details
Sanofi India Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 4481
Support 2 4449
Support 3 4395
Pivot Point : 4535
Resistance 1 4567
Resistance 2 4621
Resistance 3 4652
Sanofi India Ltd Corporate Actions
Sanofi India Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Sanofi India Ltd’s capital allocation strategies.
All
Ex-Date 07-Nov-2025 Type D Description 75.00/share@750.00% Record Date 07-Nov-2025 Ratio 750.00
Ex-Date 25-Apr-2025 Type D Description 117.00/share@1170.00% Record Date 25-Apr-2025 Ratio 1170.00
Ex-Date 03-May-2024 Type D Description 117.00/share@1170.00% Record Date 03-May-2024 Ratio 1170.00
Ex-Date 07-Mar-2024 Type D Description 50.00/share@500.00% Record Date 07-Mar-2024 Ratio 500.00
Ex-Date 28-Apr-2023 Type D Description 183.00/share@1830.00% Record Date - Ratio 1830.00
Ex-Date 28-Apr-2023 Type D Description 194.00/share@1940.00% Record Date - Ratio 1940.00
Ex-Date 05-Aug-2022 Type D Description 193.00/share@1930.00% Record Date 08-Aug-2022 Ratio 1930.00
Ex-Date 12-Apr-2022 Type D Description 309.00/share@3090.00% Record Date - Ratio 3090.00
Ex-Date 12-Apr-2022 Type D Description 181.00/share@1810.00% Record Date - Ratio 1810.00
Ex-Date 19-Apr-2021 Type D Description 240.00/share@2400.00% Record Date - Ratio 2400.00
Ex-Date 19-Apr-2021 Type D Description 125.00/share@1250.00% Record Date - Ratio 1250.00
Ex-Date 29-Jun-2020 Type D Description 243.00/share@2430.00% Record Date - Ratio 2430.00
Ex-Date 29-Jun-2020 Type D Description 106.00/share@1060.00% Record Date - Ratio 1060.00
Ex-Date 25-Apr-2019 Type D Description 66.00/share@660.00% Record Date - Ratio 660.00
Ex-Date 06-Aug-2018 Type D Description 18.00/share@180.00% Record Date 07-Aug-2018 Ratio 180.00
Ex-Date 26-Apr-2018 Type D Description 53.00/share@530.00% Record Date - Ratio 530.00
Ex-Date 31-Jul-2017 Type D Description 18.00/share@180.00% Record Date 01-Aug-2017 Ratio 180.00
Ex-Date 25-Apr-2017 Type D Description 50.00/share@500.00% Record Date - Ratio 500.00
Ex-Date 04-Aug-2016 Type D Description 18.00/share@180.00% Record Date 05-Aug-2016 Ratio 180.00
Ex-Date 13-Apr-2016 Type D Description 14.00/share@140.00% Record Date - Ratio 140.00
Ex-Date 13-Apr-2016 Type D Description 25.00/share@250.00% Record Date - Ratio 250.00
Ex-Date 13-Apr-2016 Type D Description 8.00/share@80.00% Record Date - Ratio 80.00
Ex-Date 29-Jul-2015 Type D Description 18.00/share@180.00% Record Date 30-Jul-2015 Ratio 180.00
Ex-Date 16-Apr-2015 Type D Description 11.00/share@110.00% Record Date - Ratio 110.00
Ex-Date 16-Apr-2015 Type D Description 24.00/share@240.00% Record Date - Ratio 240.00
Ex-Date 31-Jul-2014 Type D Description 10.00/share@100.00% Record Date 01-Aug-2014 Ratio 100.00
Ex-Date 16-Apr-2014 Type D Description 35.00/share@350.00% Record Date - Ratio 350.00
Ex-Date 05-Aug-2013 Type D Description 10.00/share@100.00% Record Date 06-Aug-2013 Ratio 100.00
Ex-Date 05-Apr-2013 Type D Description 29.00/share@290.00% Record Date - Ratio 290.00
Ex-Date 02-Aug-2012 Type D Description 4.00/share@40.00% Record Date 03-Aug-2012 Ratio 40.00
Ex-Date 10-Apr-2012 Type D Description 29.00/share@290.00% Record Date - Ratio 290.00
Ex-Date 03-Aug-2011 Type D Description 4.00/share@40.00% Record Date 04-Aug-2011 Ratio 40.00
Ex-Date 31-Mar-2011 Type D Description 28.00/share@280.00% Record Date - Ratio 280.00
Ex-Date 31-Mar-2011 Type D Description 23.00/share@230.00% Record Date - Ratio 230.00
Ex-Date 26-Jul-2010 Type D Description 4.00/share@40.00% Record Date 27-Jul-2010 Ratio 40.00
Ex-Date 07-Apr-2010 Type D Description 16.50/share@165.00% Record Date - Ratio 165.00
Ex-Date 30-Jul-2009 Type D Description 3.50/share@35.00% Record Date 31-Jul-2009 Ratio 35.00
Ex-Date 06-Apr-2009 Type D Description 12.50/share@125.00% Record Date - Ratio 125.00
Ex-Date 29-Jul-2008 Type D Description 3.50/share@35.00% Record Date 30-Jul-2008 Ratio 35.00
Ex-Date 03-Apr-2008 Type D Description 12.50/share@125.00% Record Date - Ratio 125.00
Ex-Date 25-Jul-2007 Type D Description 3.50/share@35.00% Record Date 26-Jul-2007 Ratio 35.00
Ex-Date 22-Mar-2007 Type D Description 12.50/share@125.00% Record Date 24-Mar-2007 Ratio 125.00
Dividends
Announcement Date 07-Nov-2025 Ex Dividend Date 07-Nov-2025 Dividend(%) 750
Announcement Date 25-Apr-2025 Ex Dividend Date 25-Apr-2025 Dividend(%) 1170
Announcement Date 03-May-2024 Ex Dividend Date 03-May-2024 Dividend(%) 1170
Announcement Date 07-Mar-2024 Ex Dividend Date 07-Mar-2024 Dividend(%) 500
Announcement Date 28-Apr-2023 Ex Dividend Date 28-Apr-2023 Dividend(%) 1830
Announcement Date 28-Apr-2023 Ex Dividend Date 28-Apr-2023 Dividend(%) 1940
Announcement Date 05-Aug-2022 Ex Dividend Date 05-Aug-2022 Dividend(%) 1930
Announcement Date 12-Apr-2022 Ex Dividend Date 12-Apr-2022 Dividend(%) 3090
Announcement Date 12-Apr-2022 Ex Dividend Date 12-Apr-2022 Dividend(%) 1810
Announcement Date 19-Apr-2021 Ex Dividend Date 19-Apr-2021 Dividend(%) 2400
Announcement Date 19-Apr-2021 Ex Dividend Date 19-Apr-2021 Dividend(%) 1250
Announcement Date 29-Jun-2020 Ex Dividend Date 29-Jun-2020 Dividend(%) 2430
Announcement Date 29-Jun-2020 Ex Dividend Date 29-Jun-2020 Dividend(%) 1060
Announcement Date 25-Apr-2019 Ex Dividend Date 25-Apr-2019 Dividend(%) 660
Announcement Date 06-Aug-2018 Ex Dividend Date 06-Aug-2018 Dividend(%) 180
Announcement Date 26-Apr-2018 Ex Dividend Date 26-Apr-2018 Dividend(%) 530
Announcement Date 31-Jul-2017 Ex Dividend Date 31-Jul-2017 Dividend(%) 180
Announcement Date 25-Apr-2017 Ex Dividend Date 25-Apr-2017 Dividend(%) 500
Announcement Date 04-Aug-2016 Ex Dividend Date 04-Aug-2016 Dividend(%) 180
Announcement Date 13-Apr-2016 Ex Dividend Date 13-Apr-2016 Dividend(%) 140
Announcement Date 13-Apr-2016 Ex Dividend Date 13-Apr-2016 Dividend(%) 250
Announcement Date 13-Apr-2016 Ex Dividend Date 13-Apr-2016 Dividend(%) 80
Announcement Date 29-Jul-2015 Ex Dividend Date 29-Jul-2015 Dividend(%) 180
Announcement Date 16-Apr-2015 Ex Dividend Date 16-Apr-2015 Dividend(%) 110
Announcement Date 16-Apr-2015 Ex Dividend Date 16-Apr-2015 Dividend(%) 240
Announcement Date 31-Jul-2014 Ex Dividend Date 31-Jul-2014 Dividend(%) 100
Announcement Date 16-Apr-2014 Ex Dividend Date 16-Apr-2014 Dividend(%) 350
Announcement Date 05-Aug-2013 Ex Dividend Date 05-Aug-2013 Dividend(%) 100
Announcement Date 05-Apr-2013 Ex Dividend Date 05-Apr-2013 Dividend(%) 290
Announcement Date 02-Aug-2012 Ex Dividend Date 02-Aug-2012 Dividend(%) 40
Announcement Date 10-Apr-2012 Ex Dividend Date 10-Apr-2012 Dividend(%) 290
Announcement Date 03-Aug-2011 Ex Dividend Date 03-Aug-2011 Dividend(%) 40
Announcement Date 31-Mar-2011 Ex Dividend Date 31-Mar-2011 Dividend(%) 280
Announcement Date 31-Mar-2011 Ex Dividend Date 31-Mar-2011 Dividend(%) 230
Announcement Date 26-Jul-2010 Ex Dividend Date 26-Jul-2010 Dividend(%) 40
Announcement Date 07-Apr-2010 Ex Dividend Date 07-Apr-2010 Dividend(%) 165
Announcement Date 30-Jul-2009 Ex Dividend Date 30-Jul-2009 Dividend(%) 35
Announcement Date 06-Apr-2009 Ex Dividend Date 06-Apr-2009 Dividend(%) 125
Announcement Date 29-Jul-2008 Ex Dividend Date 29-Jul-2008 Dividend(%) 35
Announcement Date 03-Apr-2008 Ex Dividend Date 03-Apr-2008 Dividend(%) 125
Announcement Date 25-Jul-2007 Ex Dividend Date 25-Jul-2007 Dividend(%) 35
Announcement Date 22-Mar-2007 Ex Dividend Date 22-Mar-2007 Dividend(%) 125
Bonus
No Bonus has been declared by SANOFI
Splits
No Split has been declared by SANOFI
Others
Rights No Rights has been declared by SANOFI
Sanofi India Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Sanofi India Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Sanofi India Ltd's relative performance and valuation against major competitors.
Stock Name Rubicon Research Ltd ₹677.90 (-2.62%) M. Cap (Cr) 111.68 1 Yr Return (%) NaN% P/E (TTM) PB Ratio 18.78
Stock Name Alivus Life Sciences Ltd ₹903.85 (-0.66%) M. Cap (Cr) 110.89 1 Yr Return (%) -16.31% P/E (TTM) 20.91 PB Ratio 3.94
Stock Name Sanofi Consumer Healthcare India Ltd ₹4740.20 (-0.12%) M. Cap (Cr) 109.17 1 Yr Return (%) NaN% P/E (TTM) 50.10 PB Ratio 39.98
Stock Name Sanofi India Ltd ₹4512.80 (-1.23%) M. Cap (Cr) 103.93 1 Yr Return (%) -25.74% P/E (TTM) 29.17 PB Ratio 13.55
Stock Name Procter & Gamble Health Ltd ₹5830.50 (-1.28%) M. Cap (Cr) 96.78 1 Yr Return (%) +13.89% P/E (TTM) 31.55 PB Ratio 15.60
Stock Name Blue Jet Healthcare Ltd ₹555.25 (-3.94%) M. Cap (Cr) 96.32 1 Yr Return (%) +5.31% P/E (TTM) 27.33 PB Ratio 10.42
Stock Name Marksans Pharma Ltd ₹191.73 (-0.69%) M. Cap (Cr) 86.89 1 Yr Return (%) -37.98% P/E (TTM) 24.71 PB Ratio 3.81
Sanofi India Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Sanofi India Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Dec 2024 461.70 Dec 2023 230.80 Dec 2022 398.70 Dec 2021 558.80 Dec 2020 611.10
PARTICULARS Investing Activities Dec 2024 -19.20 Dec 2023 35.50 Dec 2022 650.90 Dec 2021 630.80 Dec 2020 276.40
PARTICULARS Financing Activities Dec 2024 -392.40 Dec 2023 -878.30 Dec 2022 -1582.70 Dec 2021 -849.00 Dec 2020 -810.00
PARTICULARS Net Cash Flow Dec 2024 -109.10 Dec 2023 -612.00 Dec 2022 -533.10 Dec 2021 340.60 Dec 2020 77.50
Sanofi India Ltd Shareholding Pattern
This shows the ownership breakdown of Sanofi India Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 60.4%
Public 11.75%
Other Institutions 11.86%
FII 5.57%
Mutual Funds 10.42%
About Sanofi India Ltd
Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012. The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market. The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals. It has its own manufacturing facility at Goa. It sells products through independent distributors primarily in India.Sanofi India's products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India. The Company has its own manufacturing facility at Goa and Ankleshwar, Gujarat. It sells products through independent distributors primarily in India. Sanofi, one of the world's leading pharmaceutical companies, and its 100% subsidiary, Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.37% of its paid-up share capital. During the year 1997-98, the Joint Venture Company, Chiron Behring Vaccines Pvt Ltd started to manufacture anti-rabbies vaccine 'Rabipur'. Roussel India Ltd was amalgamated with the Company with effect from April 1, 1997 and Hoechst Nepal (Pvt) Ltd, a subsidiary Company in Nepal was wound up during the year. During the year 1999-2000, Aventis launched anti-diabetic Amaryl broad spectrum anti-infective Tavanic and line extension of anti-hypertensive Cardace H. In the year 2001, Rhone-Poulenc Rorer (India) Pvt Ltd was amalgamated with the company. The company name was changed from Hoechst Marion Roussel Ltd to Aventis Pharma Ltd with effect from July 11 2001. In July 2003. the company launched Lantus, the world's first and only once a day insulin and in December 2003, Actonel, designed for the treatment of osteoporosis was launched.In the year 2004, the company came under the control of Sanofi-Synthelabo, now called sanofi-aventis which acquired indirect control 50.1% of the company's paid-up share capital. In the year 2006, the company completed the project for setting up additional facilities for manufacturing Combiflam Tablets in Ankleshwar, Gujarat.In the year 2007, the company launched Cardace H 10 mg as a comprehensive cardiovascular treatment option in hypertension at risk patients. In May 2007, the company launched a line extension, Amaryl M. A new granulation train dedicated for production of Combiflam tablets was installed in Ankleshwar. This product which was being manufactured partly in a toll manufacturing site is now planned to be manufactured entirely in Ankleshwar.In April 2008, the company launched a new prefilled diaposable insulin pen, SoloStar for use with the 24-hour insulin Lantus. This disposable insulin pen is to be used for the treatment of hyperglycemia in people with type 1 or type 2 diabetes.On 13 December 2010, Aventis Pharma Ltd announced that it has agreed with its joint venture partner Novartis Vaccines & Diagnosics Inc. to sell its 49% shareholding in Chiron Behring Vaccines Private Limited (CBVPL) to Novartis Pharma AG and exit the joint venture. The purchase price agreed to be paid is US Dollars 22.399 million. Simultaneously, Aventis Pharma has agreed to continue to provide certain utilities and services to the Ankleshwar plant of CBVPL for a period of three years from the date of closing on mutually terms. CBVPL manufactures the anti-rabies vaccine Rabipur at its plant in Ankleshwar, which was until February 2009 distributed in India by Aventis Pharma and is presently distributed by Novartis Healthcare Private Limited. On 27 December 2010, Aventis Pharma Ltd announced that it has completed the sale of its 49% shareholding in Chiron Behring Vaccines Private Limited to Novartis Pharma AG. The company received sale consideration of Rs 100.75 crore (equivalent to US Dollars 22.399 million).On 24 August 2011, Aventis Pharma Limited (part of the Sanofi Group) announced that it has entered into a definitive agreement to acquire Universal Medicare Private Limited's business of marketing and distribution of branded nutraceutical formulations in India. Also, approximately 750 commercial employees will transition to Aventis Pharma Ltd. The transaction has been approved by the Boards of Directors of both companies. It is expected to close in the fourth quarter of 2011, subject to certain conditions precedent. Universal Medicare, (headquartered in Mumbai, India) manufactures, markets and distributes branded nutraceutical formulations in India through their sales and marketing infrastructure. With this acquisition, Aventis Pharma will advance its sustainable growth strategy in India and facilitate the creation of a consumer healthcare and wellness platform.The Registrar of Companies approved the company's change of name from Aventis Pharma Limited to Sanofi India Limited with effect from 11 May 2012. The shareholders of the company had earlier approved the name change at the Annual General Meeting held on 3 May 2012. The decision to change the name of the Group's listed entity in India comes a year after the name of the parent company was changed globally from sanofi-aventis to Sanofi in May 2011.On 9 October 2012, Sanofi India Limited announced the launch of AllStar, its first indigenously manufactured re-usable insulin pen.On 14 February 2013, Sanofi India Limited announced the launch of Combiflam Plus, a targeted, fast and effective solution for headaches, which is also gentle on the stomach. A line extension of one of Sanofi India's flagship brand Combiflam, the launch of this new product marks the company's foray into the OTC headache segment in India.On 11 November 2014, Sanofi India announced that its Board of Directors has approved of the company selling its commercial premises, being five floors and corresponding car-parking spaces in the building known as Hoechst House situated at Nariman Point, Mumbai to Bright Star Investments Private Limited and its Group companies for a total consideration of Rs 134.25 crore.On 21 July 2015, Sanofi India announced that its Board of Directors has approved of the company selling its commercial property, being land and building at Andheri, Mumbai for a consideration of Rs 111 crore. The transaction is expected to be completed in the quarter ending 30 September 2015.In August 2017, the first OTC extension of the iconic brand Combiflam was launched in the topical pain care space with the name Combiflam Icy Hot.12 February 2018, Sanofi India announced the launch of its new insulin product Toujeo. Toujeo is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.In 2019, Sanofi launched Combiflam Plus (Paracetamol and Caffeine combination). Besides, two new brands were launched, DePura by Sanofi Cal. During the year 2021-22, the Company's Nutraceuticals business, was sold as a going concern basis to Universal Nutriscience Private Limited through Slump Sale for a consideration of Rs. 587 Crore, effective on September 30, 2021. In 2021, a unique Toustarr pen, dedicated cartridge system device was launched.In 2021, Company launched a unique Toustar pen, along with dedicated ToujeoTM cartridges, addressing the need for a reusable delivery device. The Company launched multiple high-impact products in their respective categories: Frisium suspension (Neurology), Sanoxaban and Carmada (Cardiology) in 2023.The Company's Consumer Healthcare business got demerged into its wholly-owned subsidiary, Sanofi Consumer Healthcare India Limited (SCHIL), in 2023 and the Scheme of Demerger became effective on June 1, 2024. As per the provisions of the Scheme, SCHIL issued and allotted one fully paid-up equity share of SCHIL for every one fully paid-up equity share of the Company to shareholders in FY2024. In 2024, Company launched Soliquar, a best-in-class diabetes treatment for the premix segment, reinforcing the strength of its comprehensive diabetes portfolio. Additionally, strategic distribution partnerships in the Central Nervous System and Cardiovascular segments made good progress during the year.
Chairman & Independent Directo
Aditya Narayan
Registered office Sanofi Hse 117-B Saki Vihar Rd, L&T Business Park Powai, Mumbai, Maharashtra, 400072
FAX :91-22-28032000
Background
Incorporation Year 1956
Face Value ₹10.00
Market Lot 1
FAQs on Sanofi India Ltd
How to buy Sanofi India Ltd shares on NSE?
To buy Sanofi India Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Sanofi India Ltd share price today?
The Sanofi India Ltd share price on NSE is ₹4512.80 today.
What is the market cap of Sanofi India Ltd on NSE?
The company has a market capitalization of ₹10392.98.
What is the PE & PB ratio of Sanofi India Ltd?
PE is 29 and PB is 155.
What is the 52 Week High and Low of Sanofi India Ltd shares?
Sanofi India Ltd stock price high: ₹6717 Sanofi India Ltd stock price low: ₹4503.